Abstract:BACKGROUND:Elucidating the mechanism by which biallelic inactivation evolved could provide a mechanistic understanding for NF2 tumorigenesis and also a rationale for clinical management.METHODS:A cohort of 60 NF2 patients was recruited. Next-generation sequencing of tumor and paired control samples was used to explore how NF2 mutations evolve in determining the clinical phenotypes.RESULTS:In total, 60 blood samples (one from each patient) and 61 (from 35 patients) NF2-associated tumors were collected. Next-generation sequencing of the blood samples detected "first hit" NF2 mutation in 35/60 donors (58.3%), 82.9% of which (29/35) bear heterozygous germline mutations, and 17.1% (6/35) of which are mosaics with variable allelic frequency (VAF). While a number of NF2 patients were found without germline mutation, most (57/61, 93.4%) NF2-associated tumors were identified with NF2 somatic mutation. We calculated the correlation between the onset latency of mosaic and germline NF2 allele carriers with the mosaicism VAF. The mosaicism VAF is negatively and linearly correlated to clinical symptom onset latency (R2 = 0.3677, P = .00351), suggesting biallelic inactivation probability is a linear function of "first hit" prevalence in the body. The second NF2 somatic mutation occurrence time positively correlates with the onset of clinical symptoms (R2 = 0.4151, P = .02633), suggesting tumor growth is linearly proportional to the time after biallelic inactivation.CONCLUSIONS:Our results suggested that biallelic inactivation of NF2 evolved through neutral drift and preexisting first hit NF2 allele determines certain aspects of the clinical symptoms. Genetic diagnosis should be included in the diagnostic criteria and treatment consideration of NF2.

Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing

NF2-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study

Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2

Low-level germline mosaicism of a novel <i>SMARCA2</i> missense variant: Expanding the phenotypic spectrum and mode of genetic transmission

Parental Mosaicism Detection and Preimplantation Genetic Testing in Families with Multiple Transmissions of De Novo Mutations.

Assessment of parental mosaicism rates in neurodevelopmental disorders caused by apparent de novo pathogenic variants using deep sequencing

Improved sensitivity for detection of pathogenic variants in familial NF2 -related schwannomatosis

Neurofibromatosis type 1 mosaicism in patients with constitutional mismatch repair deficiency

Identification of Paternal Germline Mosaicism by MicroSeq and Targeted Next‐generation Sequencing

Parental Mosaicism in De Novo Neurodevelopmental Diseases

Origins of Biallelic Inactivation of NF2 in Neurofibromatosis Type 2

Prenatal diagnosis for neurofibromatosis type 1 and the pitfalls of germline mosaics

Personalized recurrence risk assessment following the birth of a child with a pathogenic de novo mutation

GSTM1 null genotype underpins recurrence of NF2 meningiomas

Four distinct ipsilateral vestibular schwannomas: A case of mosaic NF2 -related schwannomatosis

PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution

Clinical relevance of postzygotic mosaicism in Cornelia de Lange syndrome and purifying selection of NIPBL variants in blood

Incidental finding of a pathogenic mosaicism in the NF1 gene detected by near infrared fundus imaging – a case report

Next-Generation Sequencing-Based Preimplantation Genetic Testing for De Novo NF1 Mutations

Monozygotic twins discordant for neurofibromatosis type 1 due to a postzygotic NF1 gene mutation

Detecting Genomic Mosaicism in “de Novo” Genetic Epilepsy by Amplicon-Based Deep Sequencing